Brain Tumor
356
75
100
150
Key Insights
Highlights
Success Rate
84% trial completion
Published Results
35 trials with published results (10%)
Research Maturity
150 completed trials (42% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.1%
29 terminated out of 356 trials
83.8%
-2.8% vs benchmark
8%
27 trials in Phase 3/4
23%
35 of 150 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 150 completed trials
Clinical Trials (356)
Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures
C-SMART vs BE Well for Patients With Brain Tumors
The Neuro-protective Effects of Exercise in Children With Brain Tumors
Extracellular Impact of Ultrasound-induced Blood-brain Barrier Disruption
Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated With Cranial Radiation for Brain Tumors
Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain
REMIND Maintenance Radiotherapy for Newly Diagnosed Glioblastoma
Use of Shear Wave Elastography for Intraoperative Brain and Tumor Stiffness Measurements
Development of MRF for Characterization of Brain Tumors After Radiotherapy
Vision Improvement Through Behavioral Rehabilitation And Neuroplasticity Training
Home-based Vision Rehabilitation Guided by Brain Imaging
Asciminib With or Without Sildenafil for Brain Tumors
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
B7-H3.CD28Z.CART in CNS Neoplasms
A Study for Postoperative Delirium in Older Patients With Intracranial Tumors
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
LITT Followed by Hypofractionated RT for Recurrent Gliomas
Natural History of and Specimen Banking for People With Tumors of the Central Nervous System